GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

OliX Pharmaceuticals 226950.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

74,100

-0.94%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩14.67bn

FY2016FY2025

Net income

−₩15.74bn

FY2016FY2025

Free cash flow

−₩17.76bn

FY2016FY2025

Shareholders' equity

₩149.38bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩14.67bn₩5.68bn₩17.06bn₩9.32bn₩3.67bn₩2.47bn₩1.13bn₩302.0m₩244.0m₩391.9m
Gross profit₩14.67bn₩5.68bn₩17.06bn₩9.32bn₩3.37bn₩2.47bn₩1.11bn₩273.5m₩211.6m—
Research and development₩25.65bn₩19.54bn₩18.48bn₩17.38bn₩15.84bn₩9.48bn₩8.97bn₩5.08bn₩3.33bn—
Operating income−₩29.97bn−₩36.84bn−₩16.37bn−₩22.38bn−₩27.99bn−₩16.24bn−₩15.12bn−₩8.23bn−₩5.46bn−₩3.82bn
Net income−₩15.74bn−₩40.66bn−₩19.10bn−₩19.50bn−₩29.71bn−₩19.38bn−₩14.35bn−₩7.74bn−₩5.16bn−₩3.66bn
Diluted earnings per share-775.48-2,202.58-1,193.13-1,422.69-2,168.45-1,431.43-2,201.38-595.18-496.00-403.82

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩195.37bn₩71.25bn₩102.83bn₩132.65bn₩86.67bn₩78.58bn₩45.21bn₩55.64bn₩21.64bn₩15.15bn
Cash and short-term investments—₩12.41bn₩25.92bn₩61.87bn₩49.76bn₩68.11bn₩35.54bn₩47.06bn₩14.86bn₩9.48bn
Total liabilities₩45.29bn₩53.40bn₩52.49bn₩66.74bn₩68.15bn₩33.29bn₩3.41bn₩698.9m₩2.96bn₩2.59bn
Debt₩23.29bn₩39.19bn₩39.36bn₩44.11bn₩37.27bn₩14.53bn₩223.0m—₩1.40bn₩1.74bn
Shareholders' equity₩149.38bn₩17.85bn₩49.85bn₩65.91bn₩18.52bn₩45.29bn₩41.80bn₩54.94bn₩18.68bn₩12.56bn
Shares outstanding20m18m16m14m14m14m7m13m10m9m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−₩15.90bn−₩28.04bn−₩21.17bn−₩30.68bn−₩19.05bn−₩3.76bn−₩10.73bn−₩8.36bn−₩4.79bn−₩3.45bn
Capital spending−₩1.86bn−₩14.08bn−₩9.07bn−₩2.23bn−₩1.29bn−₩786.5m−₩1.01bn−₩500.4m−₩1.26bn−₩3.27bn
Free cash flow−₩17.76bn−₩42.12bn−₩30.24bn−₩32.92bn−₩20.34bn−₩4.55bn−₩11.74bn−₩8.86bn−₩6.05bn−₩6.72bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩2.62bn₩3.57bn₩4.53bn₩2.91bn₩6.25bn₩976.6m₩45.2m₩263.8m
Gross profit₩2.62bn₩3.57bn₩4.53bn₩2.91bn₩6.25bn₩976.6m₩45.2m₩263.8m
Operating income−₩14.00bn−₩10.79bn−₩8.46bn——−₩8.24bn−₩15.30bn−₩9.44bn
Net income−₩10.99bn−₩9.77bn₩15.39bn−₩8.66bn−₩9.20bn−₩13.27bn−₩12.16bn−₩10.51bn
Diluted earnings per share-541.24-481.27758.19-430.75-464.91-670.79-658.86-609.49
Cash from operations−₩15.43bn−₩5.72bn−₩12.16bn₩3.23bn−₩6.29bn−₩677.0m−₩28.05bn−₩19.89bn
Capital spending−₩675.0m−₩548.0m−₩384.0m−₩623.0m−₩110.0m−₩738.0m−₩14.08bn−₩10.76bn
Free cash flow−₩16.11bn−₩6.26bn−₩12.54bn₩2.60bn−₩6.40bn−₩1.42bn−₩42.12bn−₩30.65bn
Total assets₩274.07bn₩186.35bn₩195.37bn₩186.58bn₩76.09bn₩68.96bn₩71.25bn₩83.61bn
Cash and short-term investments—————₩11.54bn₩12.41bn₩11.87bn
Debt₩16.07bn₩16.96bn₩17.86bn₩18.75bn₩19.64bn₩21.86bn₩21.43bn₩28.41bn
Shareholders' equity₩236.68bn₩144.67bn₩149.38bn₩141.88bn₩22.71bn₩25.32bn₩17.85bn₩16.20bn

Financial ratios

Data as of 26 Aug 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin100.0%100.0%100.0%100.0%91.6%100.0%—
Operating margin-204.4%-649.0%-95.9%-240.1%-761.8%-656.4%—
Net margin-107.3%-716.2%-111.9%-209.2%-808.7%-783.4%—
Return on equity-10.5%-227.8%-38.3%-29.6%-160.4%-42.8%—
Return on assets-8.1%-57.1%-18.6%-14.7%-34.3%-24.7%—
Free cash flow yield——————-1.5%
Revenue growth158.3%-66.7%83.1%153.7%48.5%118.9%—
Earnings growth-61.3%112.9%-2.0%-34.4%53.3%35.1%—
Current ratio6.60x0.52x4.90x1.64x1.29x15.38x—
Debt to equity0.12x1.20x0.71x0.30x1.10x0.31x—
Equity ratio76.5%25.1%48.5%49.7%21.4%57.6%—
Interest coverage-16.47x-7.90x-4.69x-7.64x-11.28x-67.94x—
R&D as a share of sales174.9%344.1%108.3%186.5%431.2%383.1%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue16.3%42.8%—
Operating income10.2%13.0%—
Net income-6.9%-4.1%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin100.0%100.0%99.4%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings-181.1-8.7-12.2-14.3-18.9-35.1-9.6-57.5
Price to sales194.362.613.729.9152.9275.3122.3—

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 2-for-1 split · 3 Dec 2020

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.